

Antimicrobial peptide arrays for wide spectrum sensing of pathogenic bacteria

Éric Pardoux, Agnès Roux, Raphaël Mathey, Didier Boturyn, Yoann Roupioz

▶ To cite this version:

Éric Pardoux, Agnès Roux, Raphaël Mathey, Didier Boturyn, Yoann Roupioz. Antimicrobial peptide arrays for wide spectrum sensing of pathogenic bacteria. Talanta, 2019, 203, pp.322-327. 10.1016/j.talanta.2019.05.062 . hal-02565818

HAL Id: hal-02565818 https://hal.science/hal-02565818v1

Submitted on 23 Sep 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Antimicrobial peptide arrays for wide spectrum sensing of pathogenic bacteria

Éric Pardoux^{a,b}, Agnès Roux^a, Raphaël Mathey^a, Didier Boturyn^b, Yoann Roupioz^{a,*}

^aUniv. Grenoble Alpes, CNRS, CEA, INAC-SyMMES, 38000 Grenoble, France

^bUniv. Grenoble Alpes, CNRS, DCM, 38000 Grenoble, France

*Corresponding author: yoann.roupioz@cea.fr

9

5

6

7

8

10 Abstract

11 Fast detection of bacteria in samples presumed to be un-contaminated, such as blood, is of great 12 importance. Indeed, rapid diagnosis allows the set-up of appropriate antibiotic treatment. Besides clinical 13 issues, there are many other domains, such as food processing or drug manufacturing, where the strict 14 absence of any bacteria has to be assessed. Because the bacterial load found in most contaminated 15 samples is often below the limit of detection for currently validated assays, a preliminary enrichment step 16 is required to allow bacterial multiplication before proceeding to the analysis step, whatever it might be -17 cultural, immunological or molecular methods. In this study, we describe the use of a biosensor for single-18 step bacteria detection. The whole analysis is performed in less than 20 hours, during the growth phase of the micro-organisms, using an array of antimicrobial peptides (AMPs) coupled with a surface plasmon 19 20 resonance imager (SPRI). A wide range of bacterial strains are assayed, showing differentiated affinity 21 patterns with the immobilized peptides, which are confirmed by multivariate analysis. This work 22 establishes the evidence that antimicrobial peptides, mostly used so far in the antibiotic drug industry, are 23 suited for the wide-spectrum detection of unknown bacteria in samples, even at very low initial loads. 24 Moreover, the small set of AMPs that were assayed provided a specific affinity profile for each pathogen, 25 as confirmed by multivariate analyses. Furthermore, this work opens up the possibility of applying this 26 method in more complex and relevant samples such as foodstuff, urine or blood.

27

28

29 Keywords

30 Antimicrobial Peptides; Bacteria Detection; Pathogens; Surface Plasmon Resonance imaging

31

Introduction

34 The presence of bacteria in a normally sterile environment is a huge issue for human health. 35 since it can cause severe infections. Whether they originate in foodstuffs or bodily fluids such as blood or urine, the rapid and sensitive detection of pathogenic microorganisms is thus of great 36 importance. Although fast diagnosis is vital during an infection, the early detection of pathogens 37 38 is made difficult because of their low concentrations. For this reason, all samples drawn from 39 patients are first diluted and cultured in a liquid medium to increase the bacterial concentration, before proceeding to the analysis of the enriched samples. So far, culture-based techniques 40 41 have remained the gold standard in the process of diagnosing bacterial infections, though 42 several alternative methods have emerged in recent decades to devise faster and more sensitive ways to achieve bacterial detection [1]. Assays based on DNA amplification have 43 44 paved their way to a large use in clinics [2]. In spite of their faster response, these assays are 45 still time-consuming, quite expensive, and require a high level of skills. Moreover, such methods 46 may give false-positive results due to the presence of residual DNA, released from killed 47 pathogenic bacteria in some samples, for instance after antibiotic treatment. Mass spectrometry has also become widely used for the precise identification of strains [3]. However, it requires 48 49 isolated colonies of the pathogen to be grown on a solid medium and thus can only be performed several days after enrichment of the sample. Owing to these considerations, new 50 51 technologies enabling faster diagnostics are still emerging, promising simple and low-cost on-52 field implementation [4,5]. Amongst other alternatives under research, biosensors able to detect whole viable cells directly from a suspect sample are very promising. Nevertheless, each of 53 54 these exciting alternatives still require a preliminary enrichment step to increase the initial bacterial concentration above their limit of detection $(10^3 \text{ to } 10^6 \text{ CFU.ml}^{-1})$, depending on the 55 method). Surprisingly, only a few approaches couple the enrichment step with the detection 56 57 step. From this perspective, surface plasmon resonance imaging (SPRI) is a promising method. 58 Indeed, this technique is based on the optical detection of interactions at the surface of a 59 metallic layer, thus enabling the monitoring of molecular interactions without labels. Although 60 SPRI-based molecular detections are less sensitive than ELISA for biomolecular interaction studies, SPRI has been used in versatile applications from molecular studies to whole cell or 61 62 living bacteria detection, taking advantage of its real-time and label-free multiplexing abilities 63 [6,7]. This optical method has already proven its ability to successfully detect and identify pathogens starting from food matrices or blood spiked with low bacterial concentrations (few 64 CFU.ml⁻¹), using arrays of proteins and antibodies [8–11]. Such one-step approach enables 65 sensitive detection during the enrichment phase, with a wide range of probes used in parallel 66 that hence allow a high selectivity. However, although antibodies or other protein probes have 67 been proven to have high efficiency as ligands (enabling strain or even serotype identification) 68 69 they are known to present several difficulties such poor stability, difficulty of production, high 70 cost, and/or burdensome handling. It is the reason why new sets of probes have been benched 71 by researchers, the most prominent being aptamers, molecularly imprinted polymers, and 72 peptides [12]. Aptamers and molecularly imprinted polymers usually show high specificity and 73 reliability [13,14]. Nevertheless, to achieve wide spectrum detection, the multiplexing of large 74 series of probing ligands remains an issue, which limits the extent of wide spectrum detection.

- 75 Antimicrobial peptides (AMPs) are a subset of peptides presenting outstanding bactericidal
- activity [15,16]. Their binding to bacteria mainly relies on physico-chemical interactions, due to
- their polycationic or amphiphilic characteristics. Hence, they can easily attach to negatively
- charged lipopolysaccharides (LPS) anchored in the membrane of Gram-negative bacteria via
- relectrostatic interactions [17,18]. Conformational changes of their structure can also mediate the
- attachment to bacterial outer walls [19]. Although AMPs have so far mainly been investigated to
- design new drugs or antimicrobial applications [20], they are also promising ligands as potential
- alternatives to antibodies as large spectrum recognition elements towards bacteria [21,22].
 Indeed, they have naturally evolved to interact with a wide range of pathogenic bacteria and they
- are not only easy to synthesize but also easier to handle than antibodies for instance, since they
- 85 can resist harsh chemical conditions and air-drying for storage.
- 86 Surprisingly, the use of AMPs as recognition elements has only rarely been commented on in 87 the literature [23–26]. Those studies relied on the specific recognition of particular groups of bacteria, for instance targeting either a bacterial genus or a Gram class. Herein, we demonstrate 88 89 the use of AMPs in a multiplexed fashion, with several different peptidic probes exposed to a 90 contaminated sample. Thanks to the development of antimicrobial peptides arrays, we expand 91 the spectrum of detectable bacterial strains in a single one-step assay. Wide-spectrum sensing 92 of bacterial pathogens would hence be achieved. A set of AMPs inspired by previous works on 93 biosensors (see Table 1), has been produced by solid-phase synthesis and arrayed on the gold 94 surface of SPRI prisms. Such arrays were then assayed with a series of samples spiked with 95 pathogenic bacteria at low levels. Those strains are representative of major species encountered 96 in both foodborne infections and bacteremia. We were thus able to assess the performance of 97 such peptide-based sensors for wide-spectrum detection of bacteria.
- 98 Material and methods
- 99 Reagents

100 Phosphate Buffered Saline (PBS), Dimethyl Sulfoxide (DMSO), Bovine Serum Albumin (BSA),

- 101 glycerol and Tryptic Soy Broth (TSB) culture medium were purchased from Sigma-Aldrich (Saint
- 102 Quentin Fallavier, France). The solid culture medium Tryptone Soy Agar (TSA) was bought from
- bioMérieux (Lyon, France). Ultra-pure water (18,2 $M\Omega$ of resistivity) was obtained from an ELGA
- 104 PURELAB flex dispenser (Veolia Water, France).
- 105 Peptides
- 106

Name	Sequence	Targets	Technique	Ref.
Clavanin A	VFQFLGKIIHHVGNFVHGFSHVF-spacer-C-NH ₂	E. coli, S. aureus & S. Typhimurium	Electrochemical impedance	[27]
Magainin 1	$GIGKFLHSAGKFGKAFVGEIMKS\text{-}spacer-C-NH_2$	E. coli & S. Typhimurium	Fluorescence	[28]
		E. coli & Salmonella	Electrochemical capacitance	[24]
		E. coli	Fluorescence	[29]
		E. coli	Field-effect transistor	[30]
Pediocin Ped3	GKATTCIINNGAMA-spacer-C-NH2	Listeria	Microcantilevers	[31]

		monocytogenes		
PGQ	$GVLSNVIGYLKKLGTGALNAVLKQ-spacer-C-NH_2$	E. coli	Fluorescence	[32]
Leucocin A 24	C-spacer-SVNWGEAFSAGVHRLANGGNGFW-OH	Listeria monocytogenes & E. coli	Electrochemical impedance	[25, 33]
Control peptide	C-spacer-RGEWFWGNLVVSAASFGNHNAGG-OH	Scrambled version in	n of Leucocin A 24 (ne troduced)	ewly

Table 1. Set of arrayed antimicrobial peptides. Sequences are listed along with the bacteria they can detect, the detection techniques that they were used in and literature references for each. Spacer is corresponding to AEEA.

110

All peptides were synthesized by Smart Bioscience (Saint Égrève, France) through standard

112 Fmoc solid-phase method. A (2-(2-(amino)ethoxy)ethoxy)acetic acid (AEEA) spacer was

inserted between the peptide sequence and the additional terminal cysteine. When this cysteine

amino acid was added at the C-terminus, the supplier amidated this latter to achieve higher

synthesis yields, otherwise the terminal amino acid was left free. The sequences of the chosen

116 peptides are listed in *Table 1*. The certificates of analysis furnished by Smart Bioscience are

given in the Electronic Supplementary Information to confirm peptide purities and molecular

118 weights.

119 Bacterial strains

120 The Salmonella enterica subspecies enterica serovar Typhimurium (S. Typhimirium),

121 CIP104474, was obtained from the Pasteur Institute (Paris, France). Listeria monocytogenes

strain belonging to the molecular serotype IVc was acquired from the Institut Scientifique

d'Hygiène et d'Analyse (ISHA, Massy, France). It had been isolated from chicken meat. The

124 methicillin-resistant *Staphylococcus aureus* subspecies *aureus* (MRSA), ATCC43300, the

125 Staphylococcus epidermidis strain, ATCC12228, and the Escherichia coli serovar O1:K1:H7

126 (isolated from urine), ATCC11775, were all purchased from the American Type Culture

127 Collection (Manassas, Virginia, USA).

128 Culture conditions

129 Prior to each experiment, an individual bacterial colony was isolated on a TSA plate and

130 resuspended in 4 mL of sterile TSB. This bacterial culture was then incubated for 18 hours at

131 37°C under constant agitation (180 rpm). Ten-fold serial dilutions of the bacterial suspension

132 were then performed in TSB. 100 μ L of one of the ten-fold dilution series was used for sample

spiking. The 10^{-5} and 10^{-6} dilutions were plated (100 μ L on TSA plates, in triplicates) to

determine the initial bacterial concentration through manual colony counting. For each assay,

- 135 sterility controls were performed.
- 136 Peptide arraying

137 Lyophilized peptides were resuspended in DMSO at 1 $mg.mL^{-1}$ and stored at -80C. Each

138 peptide sequence was diluted at 100 μ M in PBS 1x, with 5% (v/v) of glycerol ahead of arraying

- 139 biochips. SPRi-biochips bought from Horiba Scientific (Palaiseau, France) consisted of glass
- prisms coated with a thin gold layer for direct functionalization using thiol moieties (see fig. S1 in
- 141 the Electronic Supplementary Information for more details). Peptide biochips were prepared

using a sciFLEXARRAYER (Scienion, Berlin, Germany), a piezo-dispenser allowing arraying of

- 143 4 *nL* droplets per spot. Each array resulted in 12 spots with a 450 μm diameter, and a 800 μm
- pitch between each spot. All peptides were systematically arrayed in duplicate. This step was
- 145 performed at room temperature under a humid atmosphere (75% relative humidity). After
- arraying, prisms were incubated for 18 hours at 25°C, under 94% humidity, to allow the
- 147 complete formation of self-assembled monolayers of peptides onto gold. Chips were then rinsed
 148 with ultra-pure water, dried under an argon flow for a few seconds, and stored up to several
- 149 weeks at +4°C until experiments. Effective surface functionalization was assessed by AFM
- 150 comparison with bare gold surfaces (supplemental figure S2).
- 151 Biochip conditioning and sample processing
- 152 Prisms were systematically incubated with a sterile solution of PBS+1% BSA before each
- 153 experiment to mimic interfering proteins of complex media such as blood, and to block non-
- specific interactions with gold. The surface of the prism was then rinsed with 3 mL of sterile PBS,
- before loading the biochip in the Surface Plasmon Resonance imager. 900 μ L of sterile TSB
- were then injected in the culture chamber containing the AMP-array, followed by 100 μ L of the
- 157 bacterial dilution used for spiking. Interactions of bacteria on the surface of the prisms were
- observed in real-time with the SPRi-Lab+ system (Horiba Scientific, Palaiseau, France), at 37°C.
- 159 The AMP-array was positioned so that its surface was vertical, on the sidewall of the culture
- 160 chamber. This avoids any non-specific signal from sedimenting bacteria. Sensors were
- 161 systematically discarded after use.
- 162 SPR data analysis

163 Real-time monitoring of the SPR signal began when the bacteria were spiked into the sample. 164 Regions of interest (ROI) were defined on each duplicate of AMP spots, in order to monitor the temporal change of reflectivity. Kinetics data were directly collected and processed in R 165 166 programming language. Duplicate spots of each peptide were averaged, corrected with respect 167 to the reference signal, and plotted. Peptide-free gold ROIs, coated with BSA, were chosen as 168 reference signals for non-specific interactions. Reflectivity shifts as a function of time for each 169 ROI allowed the assessment of the presence of bacteria in samples without further processing of 170 the data, by the observation of a temporal response shift. Kinetics data were used to generate a 171 database of interaction patterns between peptides and bacteria. For each spot, the first 172 derivative of the smoothed temporal data was calculated. The maximum value of this derivative. 173 as well as the corresponding smoothed reflectivity shift, were recorded. Unsupervised 174 multivariate analysis was performed on this database thanks to the FactomineR package. 175 embedded in the R software [34]. Names of targeted bacteria were used as a descriptive 176 variable, and therefore did not affect the results of the Principal Components Analysis (PCA). As 177 data were heterogeneous, they were centered and reduced. On one hand, PCA score plots were 178 used to distinguish results from one bacterial strain to another. On the other hand, they also 179 permitted a high level of repeatability of the process from different duplicates of the same assay. Hierarchical Clustering on Principal Components (HCPC) was also performed on the outcome of 180 181 the PCA. This statistical method ensured that targeted bacteria were indeed discriminated from 182 each other, based on the Euclidean distance separating the replicates in the PCA results.

183

184 Results and discussion

185 Bacterial growth monitoring by SPRI

186 The set of five bacterial strains to be detected with the peptide array has been chosen to

187 represent the diversity of pathogens frequently involved in bloodstream or urinary tract

188 infections, as well as food poisoning. The set also reflects microbial morphological diversity, with

189 both Gram-positive and negative species, including bacilli and cocci.

190 Growth kinetics monitored by SPRI of the bacteria are depicted in fig. 1, datasets retrieved from

191 those results allow defining characteristic detection times of bacteria (Supplemental Table S1)

- and affinity patterns with the peptides.
- 193





Figure 1. SPR kinetic data of the bacterial growth for five different bacterial strains cultured in tryptic soy broth at 37°C. Each curve is the average of duplicate spots for a given peptide

197 arrayed on the sensor, with subtraction of the reference signal taken on peptide free gold.

198 AMP-based arrays have permitted the detection of pathogens present at low initial concentration 199 in all samples, at most in 19 hours, and in even less than 12 hours in the majority of cases. All 200 culture conditions being the same, variations of detection signal can come from dissimilarities in 201 generation times of the different strains. Shortest detection times were for S. aureus and S. 202 epidermidis, in about 6 to 7 hours. Similar conclusions with solid based culture methods are 203 hitherto obtained in at least 24 hours. Compared to other biosensing methods using AMPs to 204 analyze pre-enriched samples, we obtained a very low limit of detection of virtually one live 205 bacterium per sample. The coupling of the enrichment step in our one-step process, not only 206 improved the safety for the operator, but also significantly improved both the overall processing 207 time and the limit of detection, by comparison to the two-steps methods described so far. 208 Naturally, the lower limit of detection comes with a longer detection time to get bacterial 209 concentrations sufficient for SPRI detection.

210 Individual peptide responses for bacterial pathogens detection

211 Peptides showed very distinct profiles of response depending on the targeted bacterial strains. 212 Individual examination of their performances is thus interesting to understand underlying 213 interactions with bacteria. Interestingly, Leucocin A 24 interacted strongly with all tested bacterial 214 strains. Nonetheless, the scrambled version of Leucocin A 24, here used as a control peptide, 215 displayed only weak to no interactions at all with any bacterial pathogen, suggesting that 216 interactions of bacteria with tethered peptides are not only governed by physico-chemical 217 mechanisms but more probably by structural interactions between peptides and bacterial 218 membranes. Such observation has already been described for therapeutic peptides [35]. 219 Clavanin A functionalized surfaces exhibited stronger SPRI responses with Staphylococci spp., 220 which are Gram-positive bacteria, although this peptide also enabled to successfully detect 221 Salmonella Typhimurium and E. coli, although with weaker interactions. With our method, 222 Magainin I only displayed mild interactions with all the tested bacteria, whatever their Gram 223 coloration (except for S. aureus which gave a very low shift). On the contrary, Ped3, a Pediocin 224 fragment, exhibited a moderate ability to detect Listeria monocytogenes, as previously described 225 [31], but surprisingly Ped3 also displayed a potent interaction with MRSA in our assay. In the 226 meantime it did not interact with S. epidermidis, although they belong to the same genus. This selective response might be caused by an association of the peptide with a peculiar receptor 227 228 specific to the membrane of MRSA. PGQ displayed interactions with E. coli, which is consistent 229 with the literature [32]. However it detected S. aureus, which is a Gram-positive strain, and had 230 no apparent interactions with Salmonella, another Gram-negative bacterium, that also displays 231 LPS, which is a hint that the interactions between PGQ and bacteria is not only mediated by 232 interacting with the latter.

These results tend to show that AMPs keep a wide spectrum of affinity towards bacteria after tethering on a surface. Moreover, association of AMPs enabled to obtain various kinetic profiles depending on the bacterial strain. Interestingly, our SPRI detection method allowed to unravel interactions which remained unobserved with other methods [25]. This could be explained by the establishment of weaker interactions between bacteria and AMPs thanks to their longer exposure time to the cultured bacteria.

239 Multivariate analyses of kinetic results

Multivariate analyses were performed to objectively assess the discrimination values of our method. To do so, PCA was performed based on reflectivity shift and sensitivity values at the

242 maximum of the first derivative for each peptide (Figure 2A). Each bacterial strain was 243 processed once on an AMP micro-array, giving 64 sets of values, from all possible combinations 244 of peptide duplicates responses at the surface. This combinatorial analyzing method ensured 245 that statistical variability of the overall response was totally represented, and that cherry picking 246 of data was avoided. Experiments on different bacterial strains with the same set of AMPs gave 247 clustered results in the PCA 2D-score plot. Moreover, those clusters of data points were well 248 segregated from each other according to the monitored pathogen: results were repeatable 249 regardless of the set of replicates in the same monitoring. The first two principal components represented only 70.3% of the total variance. This meant that the data were of high 250 251 dimensionality, thus explaining why such a good discrimination between bacterial strains could 252 be obtained. However, those first two components were sufficient in our case to clearly 253 distinguish between distinct bacterial strains. Such results underlined potential identification 254 ability of the method, although more experiments would be required to create an even more 255 exhaustive database. Results of the PCA were also used to perform a Hierarchical Clustering on 256 Principal Components (fig. 2B), leading again to a satisfying separation of the different strains in separate clusters. Such discriminated profiles came from the variety of affinities displayed by the 257 258 peptides towards the tested bacteria. Due to different physicochemical properties and structures, 259 each peptide interacted differently to Gram or genera, hence the overall combination 260 discriminated the tested strains. Multivariate analyses with appropriate databases thus allow 261 pathogen identification methods to be derived from the usual key-lock principle and enable cross-reactivity sensors as demonstrated by [36]. 262

263



264

Figure 2. Multivariate data analyses for 5 bacterial strains processed on AMP-arrays. (A) 2Dscore plot of the database generated from the kinetics of SPRI bacterial growth monitoring.
Ellipses were annotated to represent the 95% confidence interval. (B) Hierarchical Clustering on
Principal Components (HCPC) performed on the data from Fig. 2a. Distances between points
are Euclidean.

270

271 In this work, we demonstrated the suitability of AMP-arrays as powerful ligands of bacterial

272 pathogens. Traditionally studied in the field of pharmacology and antimicrobial applications,

- AMPs were revealed to be potent ligands for pathogens in biosensing applications. Not only they
- are well-adapted for the detection of bacteria in a standard culture medium such as tryptic soy

broth, but compared to antibodies, the biochip functionalization and operation were less tedious,
thanks to peptide resistance to air-drying without loss of activity in the process.

277 The use of AMPs in a multiplexed fashion allowed a fast and simple assessment of the presence 278 of pathogens even at low concentrations. Detection times ranged from 6 to 19 hours, in a one-279 step assay. This is shorter than standard methods in blood or foodstuffs, which require 280 enrichment times of usually 24 hours before confirmation of the culture positivity. Each tested 281 bacterial strain resulted in different kinetic responses on the part of the AMP-array. Ped3 even 282 exhibited a near-specific behavior, interacting almost uniquely with MRSA. Further studies could assess this point, which would be of importance in the detection of this prominent pathogen. Our 283 284 results, for instance for Leucocin A24 and its scrambled version, showed that the recognition of bacteria by AMPs is not uniquely driven by physico-chemical interactions, but also by their 285 286 secondary structuration. Moreover, tethering of the AMPs on the surface of our sensor did not 287 seem to alter this interaction with bacteria in solution. The study of the whole set of AMPs 288 interacting with live bacteria gave clearly different affinity profiles. This combined approach was 289 preferred to a biomolecular study to enable the identification of several bacterial pathogens, with 290 a single AMP set. The response to polymicrobial infections, which represent only 10% of 291 bloodstream infections [37,38], is still to be investigated to check how AMPs responses might be 292 deciphered to identify two, or more, pathogenic strains present in the same sample.

Furthermore, the small set of AMPs we used provided very distinct affinity profiles towards different pathogens, as multivariate analysis confirmed. Arrays presenting a larger collection of peptides could hence enable the possibility to create interaction profile libraries and therefore the identification of bacterial genus, species or strain of the infecting pathogen in a sample.

To the extent of our knowledge, the system we described is the first one-step biosensor assay using different multiplexed AMPs and enabling detection of several viable bacterial strains in biomedically relevant concentrations along with a discrimination capacity in a label-free assay. In the near future, this approach could be applied for the detection of any pathogen in samples such as foodstuff, urine or blood without any pre-requisite knowledge of the threat.

If these auspicious results are confirmed on a larger scale, it could permit the development of a
 one-step assay – not only able to detect common pathogens overnight – but also to identify
 them in reference to a database of affinity patterns.

- 305
- 306

Color should be used for any figures in print

- 307
- 308

309 Acknowledgements

310 EP thanks the Labex ARCANE and CBH-EUR-GS program (ANR-17-EURE-0003) for his

doctoral fellowship.

312

313 Competing interests statement

- 314 The authors declare no financial or non-financial competing interests.
- 315

316 References

[1] A. van Belkum, G. Durand, M. Peyret, S. Chatellier, G. Zambardi, J. Schrenzel, D. Shortridge,
A. Engelhardt, W.M. Dunne, Rapid clinical bacteriology and its future impact, Ann. Lab. Med. 33
(2012) 14. https://doi.org/10.2242/clm.2012.224.14

319 (2013) 14, https://doi.org/10.3343/alm.2013.33.1.14.

320 [2] O. Opota, K. Jaton, G. Greub, Microbial diagnosis of bloodstream infection: Towards

molecular diagnosis directly from blood, Clin. Microbiol. Infec. 21 (2015) 323–331,
 https://doi.org/10.1016/j.cmi.2015.02.005.

- 323 [3] A.E. Clark, E.J. Kaleta, A. Arora, D.M. Wolk, Matrix-assisted laser desorption ionization-time
- 324 of flight mass spectrometry: A fundamental shift in the routine practice of clinical microbiology,
- 325 Clin. Microbiol. Rev. 26 (2013) 547–603, https://doi.org/10.1128/cmr.00072-12.
- 326 [4] M. Guido Marcello, M.R. Tumolo, A. De Donno, T. Verri, F. Serio, F. Bagordo, A. Zizza, In
- 327 vitro diagnosis of sepsis: A review, Pathol. Lab. Med. Int. (2016) 1,
- 328 https://doi.org/10.2147/plmi.s49800.
- 329 [5] D.C. Vanegas, C.L. Gomes, N.D. Cavallaro, D. Giraldo-Escobar, E.S. McLamore, Emerging
- biorecognition and transduction schemes for rapid detection of pathogenic bacteria in food,
 Compr. Rev. Food Sci. F. (2017), https://doi.org/10.1111/1541-4337.12294.
- [6] E. Suraniti, E. Sollier, R. Calemczuk, T. Livache, P.N. Marche, M.-B. Villiers, Y. Roupioz,
- Real-time detection of lymphocytes binding on an antibody chip using SPR imaging, Lab Chip. 7
 (2007) 1206, https://doi.org/10.1039/b708292d.
- 335 [7] J.B. Fiche, J. Fuchs, A. Buhot, R. Calemczuk, T. Livache, Point mutation detection by surface
- plasmon resonance imaging coupled with a temperature scan method in a model system, Anal.
- 337 Chem. 80 (2008) 1049–1057, https://doi.org/10.1021/ac7019877.
- [8] S. Bouguelia, Y. Roupioz, S. Slimani, L. Mondani, M.G. Casabona, C. Durmort, T. Vernet, R.
 Calemczuk, T. Livache, On-chip microbial culture for the specific detection of very low levels of
 bacteria, Lab Chip. 13 (2013) 4024, https://doi.org/10.1039/c3/c50473e.
- 341 [9] L. Mondani, Y. Roupioz, S. Delannoy, P. Fach, T. Livache, Simultaneous enrichment and
- 342 optical detection of low levels of stressed *Escherichia coli* O157:H7 in food matrices, J. Appl.
- 343 Microbiol. 117 (2014) 537–546, https://doi.org/10.1111/jam.12522.
- [10] A. Morlay, A. Duquenoy, F. Piat, R. Calemczuk, T. Mercey, T. Livache, Y. Roupioz, Label-
- free immuno-sensors for the fast detection of listeria in food, Measurement. 98 (2017) 305–310, https://doi.org/10.1016/j.measurement.2016.06.038.

- 347 [11] V. Templier, T. Livache, S. Boisset, M. Maurin, S. Slimani, R. Mathey, Y. Roupioz, Biochips
- 348 for direct detection and identification of bacteria in blood culture-like conditions, Sci. Rep. 7 349 (2017), https://doi.org/10.1038/s41598-017-10072-z.
- [12] V. Templier, A. Roux, Y. Roupioz, T. Livache, Ligands for label-free detection of whole 350
- 351 bacteria on biosensors: A review, TrAC Trend. Anal. Chem. 79 (2016) 71-79,
- 352 https://doi.org/10.1016/j.trac.2015.10.015.
- 353 [13] R. Singh, M.D. Mukherjee, G. Sumana, R.K. Gupta, S. Sood, B. Malhotra, Biosensors for 354 pathogen detection: A smart approach towards clinical diagnosis, Sensor. Actuat. B-Chem. 197 (2014) 385-404, https://doi.org/10.1016/j.snb.2014.03.005.
- 355
- 356 [14] M. Shahdordizadeh, S.M. Taghdisi, N. Ansari, F.A. Langroodi, K. Abnous, M. Ramezani, 357 Aptamer based biosensors for detection of *Staphylococcus aureus*, Sensor. Actuat. B-Chem.
- 358 241 (2017) 619-635, https://doi.org/10.1016/j.snb.2016.10.088.
- 359 [15] M. Zasloff, Antimicrobial peptides of multicellular organisms, Nature. 415 (2002) 389–395, https://doi.org/10.1038/415389a. 360
- 361 [16] H.G. Boman, Antibacterial peptides: Basic facts and emerging concepts, J. Intern. Med. 254 (2003) 197-215, https://doi.org/10.1046/j.1365-2796.2003.01228.x. 362
- 363 [17] M.R. Yeaman, Mechanisms of antimicrobial peptide action and resistance, Pharmacol. Rev. 55 (2003) 27–55, https://doi.org/10.1124/pr.55.1.2. 364
- [18] L.T. Nguyen, E.F. Haney, H.J. Vogel, The expanding scope of antimicrobial peptide 365
- 366 structures and their modes of action, Trends Biotechnol. 29 (2011) 464-472,
- 367 https://doi.org/10.1016/j.tibtech.2011.05.001.
- 368 [19] M. Torrent, J. Valle, M.V. Nogués, E. Boix, D. Andreu, The generation of antimicrobial 369 peptide activity: A trade-off between charge and aggregation?, Angew. Chem. Int. Edit. 50
- 370 (2011) 10686–10689, https://doi.org/10.1002/anie.201103589.
- 371 [20] A.K. Marr, W.J. Gooderham, R.E. Hancock, Antibacterial peptides for therapeutic use:
- 372 Obstacles and realistic outlook, Curr. Opin. Pharmacol. 6 (2006) 468-472,
- 373 https://doi.org/10.1016/j.coph.2006.04.006.
- 374 [21] R.R. Silva, K.Y.P.S. Avelino, K.L. Ribeiro, O.L. Franco, M.D.L. Oliveira, C.A.S. Andrade,
- 375 Optical and dielectric sensors based on antimicrobial peptides for microorganism diagnosis. 376 Front. Microbiol. 5 (2014), https://doi.org/10.3389/fmicb.2014.00443.
- 377 [22] M. Hoyos-Nogués, F.J. Gil, C. Mas-Moruno, Antimicrobial peptides: Powerful biorecognition 378 elements to detect bacteria in biosensing technologies, Molecules. 23 (2018) 1683,
- 379 https://doi.org/10.3390/molecules23071683.
- 380 [23] N. Kulagina, K. Shaffer, F. Ligler, C. Taitt, Antimicrobial peptides as new recognition 381 molecules for screening challenging species, Sensor. Actuat. B-Chem. 121 (2007) 150-157, 382 https://doi.org/10.1016/j.snb.2006.09.044.
- 383 [24] M.S. Mannoor, S. Zhang, A.J. Link, M.C. McAlpine, Electrical detection of pathogenic
- 384 bacteria via immobilized antimicrobial peptides, P. Natl. Acad. Sci USA. 107 (2010) 19207-385 19212, https://doi.org/10.1073/pnas.1008768107.

- [25] H. Etayash, L. Norman, T. Thundat, K. Kaur, Peptide-bacteria interactions using engineered
- surface-immobilized peptides from class IIa bacteriocins, Langmuir. 29 (2013) 4048–4056,
 https://doi.org/10.1021/la3041743.
- [26] C.A. Andrade, J.M. Nascimento, I.S. Oliveira, C.V. de Oliveira, C.P. de Melo, O.L. Franco,
- 390 M.D. Oliveira, Nanostructured sensor based on carbon nanotubes and clavanin A for bacterial
- 391 detection, Colloid. Surface. B. 135 (2015) 833–839,
- 392 https://doi.org/10.1016/j.colsurfb.2015.03.037.
- 393 [27] A.G.S. Junior, M.D. Oliveira, I.S. Oliveira, R.G. Lima-Neto, S.R. Sá, O.L. Franco, C.A.
- 394 Andrade, A simple nanostructured impedimetric biosensor based on clavanin A peptide for
- bacterial detection, Sensor. Actuat. B-Chem. 255 (2018) 3267–3274,
- 396 https://doi.org/10.1016/j.snb.2017.09.153.
- [28] N.V. Kulagina, M.E. Lassman, F.S. Ligler, C.R. Taitt, Antimicrobial peptides for detection of
- 398 bacteria in biosensor assays, Anal. Chem. 77 (2005) 6504–6508,
- 399 https://doi.org/10.1021/ac050639r.
- 400 [29] M.-S. Chang, J.H. Yoo, D.H. Woo, M.-S. Chun, Efficient detection of *Escherichia coli*
- 401 O157:H7 using a reusable microfluidic chip embedded with antimicrobial peptide-labeled beads, 402 Analyst. 140 (2015) 7997–8006, https://doi.org/*10.1039/c5an01307k*.
- [30] Y. Chen, Z.P. Michael, G.P. Kotchey, Y. Zhao, A. Star, Electronic detection of bacteria using
 holey reduced graphene oxide, ACS Appl. Mater. Inter. 6 (2014) 3805–3810,
 https://doi.org/10.1021/am500364f.
- [31] S. Azmi, K. Jiang, M. Stiles, T. Thundat, K. Kaur, Detection of *Listeria monocytogenes* with
 short peptide fragments from class IIa bacteriocins as recognition elements, ACS Comb. Sci. 17
 (2015) 156–163, https://doi.org/10.1021/co500079k.
- 409 [32] S. Arcidiacono, P. Pivarnik, C.M. Mello, A. Senecal, Cy5 labeled antimicrobial peptides for
 410 enhanced detection of *Escherichia coli* O157:H7, Biosens. Bioelectron. 23 (2008) 1721–1727,
 411 https://doi.org/10.1016/j.bios.2008.02.005.
- [33] H. Etayash, L. Norman, T. Thundat, M. Stiles, K. Kaur, Surface-conjugated antimicrobial
- 413 peptide leucocin A displays high binding to pathogenic Gram-positive bacteria, ACS Appl. Mater.
 414 Inter. 6 (2014) 1131–1138, https://doi.org/10.1021/am404729c.
- 415 [34] S. Lê, J. Josse, F. Husson, FactoMineR: An R package for multivariate analysis, J. Stat.
 416 Softw. 25 (2008), https://doi.org/10.18637/jss.v025.i01.
- [35] C.D. Fjell, J.A. Hiss, R.E.W. Hancock, G. Schneider, Designing antimicrobial peptides: Form
 follows function, Nat. Rev. Drug Discov. (2011), https://doi.org/10.1038/nrd3591.
- 419 [36] J.R. Carey, K.S. Suslick, K.I. Hulkower, J.A. Imlay, K.R.C. Imlay, C.K. Ingison, J.B. Ponder,
- 420 A. Sen, A.E. Wittrig, Rapid identification of bacteria with a disposable colorimetric sensing array,
- 421 J. Am. Chem. Soc. 133 (2011) 7571–7576, https://doi.org/10.1021/ja201634d.
- 422 [37] M. Pavlaki, G. Poulakou, P. Drimousis, G. Adamis, E. Apostolidou, N.K. Gatselis, I. Kritselis,
- 423 A. Mega, V. Mylona, A. Papatsoris, A. Pappas, A. Prekates, M. Raftogiannis, K. Rigaki, K.
- 424 Sereti, D. Sinapidis, I. Tsangaris, V. Tzanetakou, D. Veldekis, K. Mandragos, H. Giamarellou, G.

- 425 Dimopoulos, Polymicrobial bloodstream infections: Epidemiology and impact on mortality, J Glob Antimicrob Re. 1 (2013) 207-212, https://doi.org/10.1016/j.jgar.2013.06.005.
- 426
- [38] C. Royo-Cebrecos, C. Gudiol, C. Ardanuy, H. Pomares, M. Calvo, J. Carratalà, A fresh look 427
- at polymicrobial bloodstream infection in cancer patients, PLoS One, 12 (2017), 428
- https://doi.org/10.1371/journal.pone.0185768. 429

Supplementary Information: Antimicrobial peptide arrays for wide spectrum sensing of pathogenic bacteria

Éric Pardoux^{a,b}, Agnès Roux^a, Raphaël Mathey^a, Didier Boturyn^b, Yoann Roupioz^{a,*}

^aUniv. Grenoble Alpes, CNRS, CEA, INAC-SyMMES, 38000 Grenoble, France

^bUniv. Grenoble Alpes, CNRS, DCM, 38000 Grenoble, France

*Corresponding author: yoann.roupioz@cea.fr

Table S1. Detection times of the presence of the different bacterial strains are determined by the timestamp of the kinetics first derivative highest value. It thus corresponds to the middle of the jump between the baseline signal and the plateau. It is given for the shortest time for each bacterial strain, associated with the peptide giving this result. Only peptides giving a strong positive signal are included in the analysis. Times are given as the average over duplicates of each peptide.

Bacterial strain	Initial concentration (CFU.mL ⁻¹)	Shortest detection time (min)	Peptide
<i>E. coli</i> ATCC11775	51	677	Clavanin A
S. Typhimurium CIP104474	6	537	Magainin I
S. aureus ATCC43300	16	433	Leucocin A 24
S. epidermidis ATCC12228	2.5·10 ³	374	Leucocin A 24
L. monocytogenes IVc	2.6·10 ³	1160	Leucocin A 24

Figure S1. (A) Scaled scheme showing characteristic dimensions of the SPRi-biochip, including a representation of the observable field of view with the SPRi-Lab+. (B) Picture of a SPRi-biochip right after a spotting.





Figure S2. AFM images of monolayers of peptides prepared in the same conditions as SPRI biochips: (A) bare gold as a reference; (B) Magainin I; (C) Leucocin A 24; (D) Control peptide. They were recorded in air using the peak force mode of a Dimension Icon AFM (from Bruker, Santa Barbara, CA). The cantilevers were triangular and using a force contact of 0.1 N/m at a 70 kHz frequency and a 0.5 Hz scan rate. Image processing was performed using the Gwyddion microscopy software.



			.			
		Certificate	e of analysis			
					•	
	Date	14/03/2016		Batch	849_s1p4f2	
Smartov	Product name	Magainin 1-Ncy	/S	Catalog #		
Biotechnology	-	-		-	-	
Product specifications						
AA sequence	C-AEEA-GIGKFL	HSAGKFGKAFV	GEIMKS-OH			
Disulfide bond	0					
Formula	C ₁₂₁ H ₁₉₃ N ₃₁ O ₃₂ S	5 ₂				
Appearance	White powder					
Theoritical average weight 2658,14 g/mol						
CAS number						
Source	Synthetic					
Counterion	TFA					
Solubility (recommendation)	10% acetonrile	solution			1 mg/mL	
	•					
Handling & Storage						
Storage	Shipped at amb	pient temperatu	re under lyoph	ilized powder. S	tore at -20°C (-4	↓°F). Do not
	freeze-thaw.					
	Aliquot sample	if required and	store at -80°C	(-112°F).		
Expiry date	Not defined					
Handling and use restriction	Use with caution	on. Might be tox	ic. Product inte	ented for resear	ch use only. not	for use in
	diagnostic or th	nerapeutic proce	edures.		,,	
Analytical results						
Observed purity rate	97,60%		Observed mon	oisotopic mass	[M+H+]+	2657,407 Da
			Theoritical mo	noisotopic mass		2656,38 Da

Chromatogram

 Sample Name :
 Sample #: 023
 Page 1 of 1

 FileName :
 C:\totalchrom\\data\Peptide cea\linjer AEEA
 Fevrier 2016\160308 magainin ncys 849s1p4f2.raw

 Date :
 3/14/2016 10:52:10 AM
 M

 Method :
 cchromolith 5-65 en 10 min.mth
 Time of Injection: 3/8/2016 11:55:35 PM

 Start Time :
 0.00 min
 End Time :
 13.00 min

 Plot Offset: -71.31 mAU
 Plot Scale: 2773.5 mAU
 High Point : 2702.15 mAU



Smartox Biotechnology 570 rue de la chimie 38400 St Martin d'Hères France

☎ +33 (0) 456 520 869
 금 +33 (0) 456 520 868
 ⊡ contact@smartox-biotech.com

Peak #	Time [min]	Area [µV·s]	Height [µV]	Area [%]	Norm. Area [%]	BL	Area/Height [s]
-	0.001	0.00	0.00	0.00	0.00		
1	0.002	33.34	325.09	0.00	0.00	BV	0.1025
2	0.005	39.66	338.72	0.00	0.00	VV	0.1171
3	0.007	18.23	286.91	0.00	0.00	VV	0.0636
4	0.010	29.97	341.26	0.00	0.00	VB	0.0878
5	0.012	24.20	256.27	0.00	0.00	BV	0.0944
6	0.015	19.32	190.70	0.00	0.00	VB	0.1013
7	0.017	8.71	188.02	7e-05	7e-05	BV	0.0463
8	0.018	11.78	221.95	0.00	0.00	VB	0.0531
9	7.444	13.25	278.45	0.00	0.00	BV	0.0476
10	7.447	67.80	709.43	0.00	0.00	VV	0.0956
11	7.450	161.57	1440.70	0.00	0.00	VV	0.1121
12	7.530	11494288.40	2.54e+06	97.60	97.60	VE	4.5342
13	7.645	80123.98	70666.35	0.68	0.68	EV	1.1338
14	7.647	9323.03	72519.37	0.08	0.08	VV	0.1286
15	7.650	11590.99	72555.12	0.10	0.10	VV	0.1598
16	7.653	12378.38	72682.91	0.11	0.11	VV	0.1703
17	7.655	11828.25	72501.87	0.10	0.10	VV	0.1631
18	7.657	156665.19	72211.00	1.33	1.33	VE	2.1695
19	7.749	482.05	363.95	0.00	0.00	*EB	1.3245
		11777108.11	2 97e+06	100.00	100.00		

Smartox Biotechnology 570 rue de la chimie 38400 St Martin d'Hères France



		Certificat	e of analysis			
	Date	21/03/2016		Batch	847_s1p1f1	
Smartov	Product name	clavaninA		Catalog #		
Biotechnology						
Product specifications						
	1					
AA sequence	VFQFLGKIIHHV	GNFVHGFSHVF	-AEEA-C-NH2			
Disulfide bond	0					
Formula	C ₁₄₀ H ₂₀₁ N ₃₇ O ₃₀ S	5				
Appearance	White powder					
Theoritical average weight	2914,39	g/mol				
CAS number						
Source	Synthetic					
Counterion	TFA					
Solubility (recommendation)	50% of Acetoni	trile solution			1 mg/mL	
Handling & Storage						
Storage	Shinned at am	ient temperati	ire under lyonh	ilized powder	Store at 20°C (-/	1°E) Do not
Storage	freeze-thaw				51010 01 20 01	+ 1 <i>J</i> . Do not
	Aliquot sample	if required and	store at -80°C	(_112°E)		
Expiry date	Not defined	in required and		(112 1).		
Handling and use restriction	Use with cautio	n Might he to	xic Product inte	ented for resea	urch use only not	for use in
	diagnostic or th	nerapeutic proc	edures.		iren use only, not	
			2001201			
Analytical results						
Observed purity rate	93,47%		Observed mon	oisotopic mass	5 [M+H+]+	2913,41 Da
			Theoritical mo	noisotopic mas	SS	2912,50 Da





☎ +33 (0) 456 520 869
 용 +33 (0) 456 520 868
 contact@smartox-biotech.com

Smartox Biotechnology 570 rue de la chimie 38400 St Martin d'Hères France

Peak #	Time [min]	Area [µV·s]	Height [µV]	Area [%]	Norm. Area [%]	BL	Area/Height [s]
-	0.001	0.00	0.00	0.00	0.00		
1	8 477	16.06	278 50	0.00	0.00	BB	0.0577
2	8 479	31.83	387.81	0.00	0.00	BB	0.0821
3	8 482	35.38	401.57	0.00	0.00	BV	0.0881
4	8 485	44.93	382.61	0.00	0.00	Ŵ	0 1174
5	8 487	33.96	351.45	0.00	0.00	VB	0.0966
ĕ	8 4 9 0	42.92	404 71	0.00	0.00	BV	0.1061
7	8 4 9 3	46.59	505.61	0.00	0.00	Ŵ	0.0921
	8 4 9 5	68.36	631 11	0.00	0.00	ŵ	0.1083
ğ	8 4 9 8	87.27	771.69	0.00	0.00	ŵ	0.1131
10	8 501	142.81	1074 51	0.00	0.00	ŵ	0.1329
11	8 503	172.67	1511.97	0.00	0.00	ŵ	0.1020
12	8 506	275.47	2096.31	0.00	0.00	ŵ	0.1314
13	8 509	392.05	2721 50	0.00	0.00	ŵ	0 1441
14	8 511	450.27	3376.96	0.00	0.00	ŵ	0 1333
15	8 514	645.48	4216 42	0.01	0.01	ŵ	0.1531
16	8 5 1 9	1552.63	5894 62	0.02	0.02	ŵ	0.2634
17	8 522	1010.98	6789 15	0.01	0.01	ŵ	0 1489
18	8 525	1162.84	7819 38	0.01	0.01	vv	0 1487
19	8 527	1327 63	8878 12	0.02	0.02	Ŵ	0 1495
20	8 530	1510.31	10089 78	0.02	0.02	Ŵ	0 1497
21	8 552	21521.76	23881.49	0.26	0.26	Ŵ	0.9012
22	8.554	3916.28	25032.12	0.05	0.05	Ŵ	0.1565
23	8.557	4627.25	25713.31	0.06	0.06	Ŵ	0.1800
24	8.559	4379.62	26019.79	0.05	0.05	Ŵ	0.1683
25	8.562	9901.71	25954.16	0.12	0.12	VV	0.3815
26	8.567	8309.68	25070.62	0.10	0.10	VV	0.3315
27	8.572	1915.96	24033.86	0.02	0.02	VV	0.0797
28	8.575	3368.81	23805.12	0.04	0.04	VV	0.1415
29	8.578	3689.36	23908.68	0.04	0.04	VV	0.1543
30	8.581	3922.28	24271.94	0.05	0.05	VV	0.1616
31	8.583	3398.55	24902.34	0.04	0.04	VV	0.1365
32	8.586	4054.49	25875.04	0.05	0.05	VV	0.1567
33	8.589	4230.50	27041.78	0.05	0.05	VV	0.1564
34	8.594	9099.73	29860.21	0.11	0.11	VV	0.3047
35	8.605	21091.32	35763.97	0.25	0.25	VV	0.5897
36	8.607	6816.61	36658.49	0.08	0.08	VV	0.1859
37	8.610	4935.51	36876.89	0.06	0.06	VV	0.1338
38	8.612	48075.96	36873.03	0.58	0.58	VV	1.3038
39	8.639	2164.07	19942.86	0.03	0.03	VV	0.1085
40	8.642	2768.11	20291.31	0.03	0.03	VV	0.1364
41	8.661	28708.81	32007.54	0.35	0.35	VV	0.8969
42	8.663	5225.54	33395.14	0.06	0.06	VV	0.1565
43	8.666	5435.57	34540.10	0.07	0.07	VV	0.1574
44	8.669	5611.25	35652.13	0.07	0.07	VV	0.1574
45	8.671	5802.05	36885.86	0.07	0.07	VV	0.1573
46	8.757	7759165.19	2.05e+06	93.47	93.47	VE	3.7797
47	8.857	68344.03	66184.49	0.82	0.82	EV	1.0326
48	8.860	11164.51	69517.84	0.13	0.13	VV	0.1606

Peak #	Time [min]	Area [µV·s]	Height [µV]	Area [%]	Norm. Area [%]	BL	Area/Height [s]
49	8.863	9991.57	69834.22	0.12	0.12	vv	0.1431
50	8.866	11781.87	70390.71	0.14	0.14	Ŵ	0.1674
51	8.869	9892.04	70958.47	0.12	0.12	VV	0.1394
52	8.871	11412.92	71800.34	0.14	0.14	VV	0.1590
53	8.874	11541.86	72583.86	0.14	0.14	VV	0.1590
54	8.877	12634.93	73338.95	0.15	0.15	VV	0.1723
55	8.879	12356.59	73858.97	0.15	0.15	VV	0.1673
56	8.882	12926.44	74076.95	0.16	0.16	VV	0.1745
57	8.884	137569.02	73814.29	1.66	1.66	VB	1.8637
58	8.958	47.52	258.37	0.00	0.00	BV	0.1839
59	8.962	16.14	314.76	0.00	0.00	VB	0.0513
60	8.964	43.00	243.67	0.00	0.00	BV	0.1764
61	8.967	30.23	408.93	0.00	0.00	VB	0.0739
62	8.970	14.32	207.22	0.00	0.00	BB	0.0691
63	8.975	11.93	226.30	0.00	0.00	BB	0.0527
64	8.978	18.48	265.82	0.00	0.00	BB	0.0695
65	8.980	8.50	159.61	0.00	0.00	BB	0.0533
66	8.983	25.92	318.15	0.00	0.00	BB	0.0815
67	8.985	7.18	168.91	9e-05	9e-05	BV	0.0425
68	8.986	13.73	261.55	0.00	0.00	VB	0.0525
69	8.988	56.86	272.05	0.00	0.00	BV	0.2090
70	8.993	31.48	272.06	0.00	0.00	VB	0.1157
71	8.996	51.16	213.86	0.00	0.00	BV	0.2392
72	8.999	10.67	333.89	0.00	0.00	VB	0.0320
73	9.004	25.92	269.75	0.00	0.00	BB	0.0961
74	9.006	25.22	193.51	0.00	0.00	BB	0.1303
75	9.009	20.37	176.06	0.00	0.00	BB	0.1157
76	9.012	12.69	261.76	0.00	0.00	BV	0.0485
77	9.012	18.72	330.46	0.00	0.00	VB	0.0567
78	9.015	16.03	188.59	0.00	0.00	*BB	0.0850

8301308.27 3.62e+06 100.00 100.00



		Certificat	e of analysis			
		Certificati	e or unurysis			
	Date	22/03/2016		Batch	850 s2p1r1	
	Product name	peptide Contrô	le	Catalog #		
Smartox. Biotechnology					<u> </u>	
Product specifications						
AA sequence	C-AEEA-RGEWF	WGNLVVSAASF	GNHNAGG-OH	l		
Disulfide bond	0					
Formula	C ₁₁₉ H ₁₉₄ N ₃₆ O ₃₄ S	5				
Appearance	White powder					
Theoritical average weight	2681,89	g/mol				
CAS number						
Source	Synthetic					
Counterion	TFA					
Solubility (recommendation)	50 % of Aceton	itrile solution			1 mg/mL	
Handling & Storage						
Storage	Shipped at amb	pient temperatu	ire under lyoph	ilized powder.	Store at -20°C (-4	l°F). Do not
	freeze-thaw.					
	Aliquot sample	if required and	store at -80°C	(-112°F).		
Expiry date	Not defined					
Handling and use restriction	Use with caution	on. Might be tox	ic. Product inte	ented for resea	rch use only, not	for use in
	diagnostic or th	nerapeutic proce	edures.			
Analytical results						
Observed purity rate	90,49%		Observed mon	oisotopic mass	[M+H+]+	2681,17 Da
			Theoritical mo	noisotopic mas	S	2680,22 Da

Chromatogram

 Sample Name :
 Sample #: 020
 Page 1 of 1

 FileName : C:\totalchrom\data\Peptide ceal\injer AEEA fevrier 2016\160314 peptide controle 850 s2p1r1.raw

 Date : 3/21/2016 2:42:49 PM

 Method : cchromolith 5-95 en 10 min.mth

 Start Time : 0.00 min
 End Time : 13.00 min

 Low Point : -126.41 mAU
 Plot Scale: 2528.2 mAU



+33 (0) 456 520 868 contact@smartox-biotech.com

=

Smartox Biotechnology 570 rue de la chimie 38400 St Martin d'Hères France

Peak #	Time [min]	Area [µV·s]	Height [µV]	Area [%]	Norm. Area [%]	BL	Area/Height [s]
-	0.001	0.00	0.00	0.00	0.00		
1	0.002	42.54	245.68	0.00	0.00	BV	0.1732
2	0.007	28.29	356.69	0.00	0.00	VB	0.0793
3	4.869	86010.57	65647.89	1.35	1.35	BV	1.3102
4	4.874	7756.18	59133.80	0.12	0.12	VV	0.1312
5	4.898	154870.24	83562.89	2.43	2.43	VV	1.8533
6	4.944	271621.09	161956.69	4.27	4.27	*VB	1.6771
7	5.002	18420.50	16740.93	0.29	0.29	BB	1.1003
8	5.045	49368.87	34018.14	0.78	0.78	BV	1.4513
9	5.085	8310.72	14378.72	0.13	0.13	VV	0.5780
10	5.086	8566.17	14587.51	0.13	0.13	*VB	0.5872
11	5.215	5755579.60	2.20e+06	90.49	90.49	*BB	2.6139
		6360574.77	2.65e+06	100.00	100.00		



		Cortificato of	Fanalysis			
		Certificate of	allalysis			
	Date Product name	21/03/2016 Magainin 1-Ccvs	Ba	atch atalog #	851_s1p1f1	
Smartox. Biotechnology					_ <u>I</u>	
Product specifications						
	1					
AA sequence	GIGKFLHSAGKF	GKAFVGEIMKS-AEE	EA-C-NH2			
Disulfide bond	0					
Formula	C ₁₂₁ H ₁₉₄ N ₃₂ O ₃₁	52				
Appearance	White powder					
Theoritical average weight	2657,16	g/mol				
CAS number						
Source	Synthetic					
Counterion	TFA					
Solubility (recommendation)	10% acetonrile	solution			1 mg/mL	
Handling & Storage						
Storage	Shipped at aml	pient temperature ι	under lyophiliz	ed powder.	Store at -20°C (-4°F). Do not
	freeze-thaw.					
	Aliquot sample	if required and sto	re at -80°C (-1	12°F).		
Expiry date	Not defined					
Handling and use restriction	Use with caution	on. Might be toxic. I	Product intent	ed for resea	arch use only, no	t for use in
	diagnostic or t	nerapeutic procedu	res.			
Analytical results						
		<u>.</u>				-
Observed purity rate	95,61%	Obs	served monois	otopic mas	s [M+H+]+	2656,39 Da
		The	eoritical monoi	isotopic ma	SS	2655,40 Da

☎ +33 (0) 456 520 869 용 +33 (0) 456 520 868 ⊆ contact@smartox-biotech.com

Smartox Biotechnology 570 rue de la chimie 38400 St Martin d'Hères France



Chromatogram

Peak #	Time [min]	Area [µV·s]	Height [µV]	Area [%]	Norm. Area [%]	BL	Area/Height [s]
199	7.359	37.65	431.30	0.00	0.00	BV	0.0873
200	7.362	62.26	593.15	0.00	0.00	VV	0.1050
201	7.365	132.78	1181.71	0.00	0.00	VV	0.1124
202	7.367	219.66	1/20.05	0.00	0.00	VV	0.1277
203	7 373	322.40	2423.05	0.01	0.01	Ŵ	0.1331
205	7.375	581.18	3759.34	0.01	0.01	ŵ	0.1546
206	7.378	628.47	4262.35	0.01	0.01	Ŵ	0.1474
207	7.381	722.46	4530.80	0.01	0.01	VV	0.1595
208	7.383	667.64	4561.89	0.01	0.01	VV	0.1464
209	7.386	652.02	4427.26	0.01	0.01	VV	0.1750
210	7 391	985.33	3528.49	0.01	0.01	ŵ	0.1008
212	7.396	476.71	2308.35	0.01	0.01	Ŵ	0.2065
213	7.399	89.65	1576.89	0.00	0.00	VV	0.0569
214	7.401	183.94	1213.24	0.00	0.00	VV	0.1516
215	7.405	88.98	771.10	0.00	0.00	VV	0.1154
210	7 4 10	47.38	250.60	0.00	0.00	VR	0.1230
218	7.413	22.68	281.60	0.00	0.00	BB	0.0805
219	7.415	16.74	252.52	0.00	0.00	BB	0.0663
220	7.418	20.51	300.09	0.00	0.00	BV	0.0683
221	7.421	48.42	514.08	0.00	0.00	W	0.0942
222	7.423	97.45	822.22	0.00	0.00	VV	0.1185
223	7 4 20	122.00	990.43 1445.47	0.00	0.00	Ŵ	0.1225
225	7.431	260.02	1923.75	0.00	0.00	ŵ	0.1352
226	7.434	314.22	2168.52	0.01	0.01	Ŵ	0.1449
227	7.437	380.62	2620.35	0.01	0.01	VV	0.1453
228	7.439	440.35	2809.65	0.01	0.01	VV	0.1567
229	7.442	428.67	2836.71	0.01	0.01	VV VV	0.1511
230	7 445	363 58	2070.04	0.01	0.01	ŵ	0.1055
232	7.449	304.55	2000.89	0.01	0.01	ŵ	0.1522
233	7.452	108.39	1481.06	0.00	0.00	VV	0.0732
234	7.452	113.68	1357.36	0.00	0.00	VV	0.0838
235	7.454	45.28	776.93	0.00	0.00	VV	0.0583
230	7.455	40.84	072.88	0.00	0.00	RB	0.0681
238	7.460	7.43	151.63	0.00	0.00	BV	0.0490
239	7.460	18.64	318.54	0.00	0.00	VB	0.0585
240	7.482	7.09	184.32	0.00	0.00	BB	0.0384
241	7.484	14.11	191.15	0.00	0.00	BB	0.0738
242	7 4 9 1	24.33	280.00	0.00	0.00	BU	0.0801
244	7.493	86.36	687.81	0.00	0.00	Ŵ	0.1256
245	7.495	129.47	1159.81	0.00	0.00	VV	0.1116
246	7.498	199.49	1744.68	0.00	0.00	VV	0.1143
247	7.501	342.53	2635.92	0.01	0.01	VV.	0.1299
248	7.504	487.35	3000.54	0.01	0.01	Ŵ	0.1331
240	7 538	11995 69	26686 43	0.30	0.30	ŵ	0 4495
251	7.541	4898.89	27627.31	0.08	0.08	Ŵ	0.1773
252	7.543	3932.89	28745.32	0.07	0.07	VV	0.1368
253	7.641	5583836.78	1.60e+06	95.61	95.61	VB	3.4968
254	7 702	44.38	133.65	0.00	0.00	BB	0.3321
256	7 799	9 21	165.21	0.00	0.00	BB	0.2558
257	7.804	8.21	159.30	0.00	0.00	BB	0.0515
258	7.810	23.68	256.80	0.00	0.00	BB	0.0922
259	7.812	7.74	133.23	0.00	0.00	BB	0.0581
260	7.814	18.66	206.72	0.00	0.00	BR	0.1077
262	7 820	38.38	330 73	0.00	0.00	VB	0.0014
263	7.823	33.27	345.67	0.00	0.00	BV	0.0962
264	7.826	24.46	242.86	0.00	0.00	VB	0.1007
265	7.828	13.35	179.63	0.00	0.00	BB	0.0743
266	7.831	25.25	331.23	0.00	0.00	BB	0.0762
267	7.834	20.37	229.47	0.00	0.00	BV	0.0888
269	7.836	7 44	187.96	0.00	0.00	VB	0.0429
270	7.839	29.06	310.31	0.00	0.00	BV	0.0936
271	7.842	23.68	282.79	0.00	0.00	VB	0.0837
272	7.844	27.16	287.98	0.00	0.00	BB	0.0943
2/3	1.847	34.04	353.19	0.00	0.00	ВV	0.0964



		• ····								
		Certificate	e of analysis							
					1					
	Date	21/03/2016		Batch	852_s1p1f2					
Smartov	Product name	peptide PGQ		Catalog #						
Biotechnology										
Droduct coocifications										
AA sequence	GVLSNVIGYLKK	LGTGALNAVLKC	AEEA-C-NH2							
Disulfide bond	0									
Formula	C ₁₂₁ H ₂₁₁ N ₃₃ O ₃₄	5								
Appearance	White powder									
Theoritical average weight	2704,23	2704.23 g/mol								
CAS number	,	0,								
Source	Synthetic									
Counterion	TFA									
Solubility (recommendation)	Water 1 mg/mL									
Handling & Storage										
	-									
Storage	Shipped at ambient temperature under lyophilized powder. Store at -20°C (-4°F). Do not									
	freeze-thaw.									
	Aliquot sample if required and store at -80°C (-112°F).									
Expiry date	Not defined									
Handling and use restriction	lling and use restriction Use with caution. Might be toxic. Product intented for research use only, not for use in									
	diagnostic or th	nerapeutic proce	edures.							
Analytical results										
Observed purity rate	97,92%		Observed mon	oisotopic mass	[M+H+]+	2703,59 Da				
			Theoritical mo	noisotopic mass		2702,55 Da				

Chromatogram

 Sample Name :
 Sample #: 026
 Page 1 of 1

 FileName : C:\totalchrom\data\Peptide cea\linjer AEEA fevrier 2016\160304 pgg 852s1p1f2.raw

 Date : 3/22/2016 9:26:22 AM

 Method : cchromolith 5-55 en 10 min.mth

 Time of Injection: 3/4/2016 11:22:27 PM

 Start Time : 0.00 min End Time : 13.00 min

 Plot Offset: 48.26 mAU

 Plot Scale: 301.3 mAU



☎ +33 (0) 456 520 869
 ♣ +33 (0) 456 520 868
 ☑ contact@smartox-biotech.com

Smartox Biotechnology 570 rue de la chimie 38400 St Martin d'Hères France

Peak #	Time [min]	Area [µV·s]	Height [µV]	Area [%]	Norm. Area [%]	BL	Area/Height [s]	Peak #	Time [min]	Area [µV·s]	Height [µV]	Area [%]	Norm. Area [%]	BL	Area/Height [s]
-	0.001	0.00	0.00	0.00	0.00			49	10.829	24.04	263.16	0.00	0.00	BV	0.0914
1	0.003	26.52	301.71	0.00	0.00	BV	0.0879	50	10.832	26.03	335.05	0.00	0.00	VB	0.0777
2	0.005	29.05	300.47	0.00	0.00	VB	0.0967	51	10.837	24.58	307.76	0.00	0.00	BV	0.0799
3	0.008	24.28	289.71	0.00	0.00	BV	0.0838	52	10.840	30.64	345.61	0.00	0.00	VB	0.0886
4	0.011	22.94	211.76	0.00	0.00	VB	0.1083	53	10.843	9.97	170.24	0.00	0.00	BA	0.0586
5	0.014	28.98	347.00	0.00	0.00	ΒV	0.0835	54	10.846	29.15	328.11	0.00	0.00	VB	0.0888
6	0.016	22.64	288.75	0.00	0.00	VB	0.0784	55	10.848	130.09	337.24	0.02	0.02	ND ND	0.4053
7	0.019	21.52	304.84	0.00	0.00	BB	0.0706	57	10.007	20.30	200.40	0.00	0.00	RV BV	0.0923
8	0.022	22.65	211.65	0.00	0.00	BV	0.1070	58	10.872	20.12	300.86	0.00	0.00	VB	0.0669
9	0.024	16.55	272.74	0.00	0.00	VV	0.0607	59	10.875	52 51	312.16	0.00	0.00	ΒV	0 1682
10	0.027	18.71	212.36	0.00	0.00	VB	0.0881	60	10.880	22.81	265.18	0.00	0.00	VB	0.0860
11	10.520	19.13	255.53	0.00	0.00	BB	0.0749	61	10.883	17.27	225.33	0.00	0.00	BB	0.0767
12	10.522	23.27	169.37	0.00	0.00	BA	0.1374	62	10.885	25.49	158.79	0.00	0.00	BV	0.1606
13	10.520	15.88	243.23	0.00	0.00	VB	0.0653	63	10.887	21.14	160.78	0.00	0.00	VV	0.1315
14	10.528	25.54	305.91	0.00	0.00	BB	0.0835	64	10.891	30.08	353.87	0.00	0.00	VB	0.0850
10	10.551	10.40	203.72	0.00	0.00		0.0023	65	10.894	37.96	366.72	0.01	0.01	BV	0.1035
17	10.534	22.07	281.86	0.00	0.00	ŵ	0.0904	60	10.896	106.50	405.85	0.01	0.01	VV VV	0.2624
18	10.538	20.20	159.49	0.00	0.00	VR	0.0323	10	10.902	78.88	712.83	0.01	0.01	Ŵ	0.1229
19	10.542	26.52	341 29	0.00	0.00	BV	0.0777	69	10.004	123.82	952.87	0.01	0.01	vv	0.1273
20	10.544	31.06	340.05	0.00	0.00	vv	0.0913	70	10,910	156 64	1079 11	0.02	0.02	vv	0 1452
21	10.547	29.26	292.68	0.00	0.00	vv	0 1000	71	10.912	181.51	1279.32	0.02	0.02	Ŵ	0.1419
22	10.550	42.07	413.02	0.01	0.01	vv	0.1019	72	10.915	204.72	1426.92	0.03	0.03	VV	0.1435
23	10.552	38.50	376.56	0.01	0.01	VV	0.1022	73	10.917	235.91	1479.75	0.03	0.03	VV	0.1594
24	10.555	62.27	409.42	0.01	0.01	VV	0.1521	74	10.920	273.92	1858.63	0.04	0.04	VV	0.1474
25	10.558	32.11	364.78	0.00	0.00	VV	0.0880	75	10.922	281.59	1868.97	0.04	0.04	VV	0.1507
26	10.560	41.41	404.20	0.01	0.01	VV	0.1024	/6	10.926	352.73	2232.73	0.05	0.05	VV	0.1580
27	10.563	36.64	364.94	0.01	0.01	VV	0.1004	70	10.928	317.93	2428.64	0.04	0.04	VV VV	0.1309
28	10.566	37.36	416.20	0.01	0.01	VV	0.0898	70	10.931	310.00	2020.02	0.08	0.08	Ŵ	0.2247
29	10.568	44.15	421.07	0.01	0.01	VV	0.1048	80	10.936	390.51	2838.37	0.04	0.04	vv	0.1376
30	10.571	54.39	527.65	0.01	0.01	VV	0.1031	81	10.939	408.08	2942.89	0.06	0.06	vv	0.1387
31	10.574	67.34	543.85	0.01	0.01	VV	0.1238	82	10.942	560.08	3054.82	0.08	0.08	VV	0.1833
32	10.576	61.73	545.19	0.01	0.01	VV	0.1132	83	10.944	448.63	3033.79	0.06	0.06	VV	0.1479
33	10.578	/2./6	450.51	0.01	0.01	VV	0.1615	84	10.947	474.21	3067.70	0.07	0.07	VV	0.1546
34	10.582	96.41	172.89	0.01	0.01	VV.	0.1247	85	10.950	409.57	3020.90	0.06	0.06	VV	0.1356
35	10.584	140.43	1023.12	0.02	0.02	VV.	0.1373	86	10.952	425.28	2909.80	0.06	0.06	VV	0.1462
30	10.587	169.01	1280.76	0.02	0.02	~~~	0.1320	87	10.954	1651.34	2754.66	0.23	0.23	VV.	0.5995
20	10.590	220.00	2100 72	0.03	0.03	Ŵ	0.1332	00 90	10.905	324.40	2294.14	0.04	0.04	Ŵ	0.1414
30	10.595	385 55	2803.13	0.04	0.04	ŵ	0.1275	90	10.900	200.95	1192.57	0.13	0.13	ŵ	0.1685
40	10.659	713376.20	177068 23	97.92	97.92	VĒ	4 0288	91	10.984	457.77	1108.28	0.06	0.06	VB	0.4130
41	10 778	480.16	541 27	0.07	0.07	έV	0.8871	92	10.998	77.21	366.21	0.01	0.01	BB	0.2108
42	10.784	52.68	487.43	0.01	0.01	VB	0.1081	93	11.003	33.23	397.56	0.00	0.00	BV	0.0836
43	10,789	72.49	350.17	0.01	0.01	BV	0.2070	94	11.006	124.41	388.92	0.02	0.02	VB	0.3199
44	10.795	126.34	335.42	0.02	0.02	VB	0.3767	95	11.019	31.35	261.11	0.00	0.00	ΒV	0.1201
45	10.805	92.42	355.28	0.01	0.01	BB	0.2601	96	11.024	44.46	289.73	0.01	0.01	VB	0.1535
46	10.813	25.22	318.08	0.00	0.00	BB	0.0793	97	11.030	54.36	333.48	0.01	0.01	BV	0.1630
47	10.816	34.37	379.36	0.00	0.00	BB	0.0906	98	11.035	18.22	232.92	0.00	0.00	VB	0.0782
48	10.819	91.53	314.50	0.01	0.01	BB	0.2910	100	11.038	33.04	335.20	0.00	0.00		0.1000
								100	11.043	21.65	279.85	0.00	0.00	BV	0.0003
								102	11.045	33.30	347.73	0.00	0.00	VB	0.0958
								103	11.051	29.02	369.13	0.00	0.00	BB	0.0786
								104	11.054	28.70	373.50	0.00	0.00	BV	0.0768
								105	11.056	31.06	291.98	0.00	0.00	VV	0.1064
								106	11.059	25.19	342.14	0.00	0.00	VB	0.0736
								107	11.062	43.11	273.54	0.01	0.01	BB	0.1576
								108	11.067	10.15	148.59	0.00	0.00	BV	0.0683
								110	11.070	13.50	249.00	0.00	0.00	RD RD	0.0043
								110	11.071	17.04	140.82	0.00	0.00	00	0.1100

109 11.070 110 11.071 111 11.074 112 11.077 113 11.083 114 11.086 146.92 122.07 176.29 308.59 0.00 0.00 BB 16.24 14.82 25.45 0.00 0.00 0.00 0.00 0.00 0.00 BB BB BV 15.50 173.15 0.00 0.00 *VB 728513.35 264018.78 100.00 100.00

0.0543 0.1160 0.1330 0.0841 0.0825

0.0895



☎ +33 (0) 456 520 869
 ♣ +33 (0) 456 520 868
 ⓓ contact@smartox-biotech.com

		Contificat	a of analysis					
		Certificat	e of analysis					
	Data	22/02/2016		Datah	052 -1-1-2			
	Date	22/03/2016		Batch	853_s1p1r2			
Smartox	Product name	Leucocin A 24		Catalog #				
Biotechnology								
Product specifications								
AA sequence	C-AEEA-SVNW0	GEAFSAGVHRLA	NGGNGFW-OH					
Disulfide bond	0							
Formula	C ₁₁₉ H ₁₇₀ N ₃₆ O ₃₄ S	5						
Appearance	White powder							
Theoritical average weight	2681,89	g/mol						
CAS number								
Source	Synthetic							
Counterion	TFA							
Solubility (recommendation)	ommendation) 50% of Acetonitrile solution 1 mg/mL							
Handling & Storage								
Storage Shipped at ambient temperature under lyophilized powder. St						°F). Do not		
	freeze-thaw.							
	Aliquot sample if required and store at -80°C (-112°F).							
Expiry date	Not defined							
Handling and use restriction	Use with caution. Might be toxic. Product intented for research use only, not for use in							
	diagnostic or th	nerapeutic proc	edures.					
Analytical results								
Observed purity rate	90,34%		Observed mon	oisotopic mass	[M+H+]+	2681,12 Da		
			Theoritical mo	noisotopic mas	S	2680,22 Da		

Chromatogram

 Sample Name :
 Sample #: 027
 Page 1 of 1

 FileName : C:\totalchrom\data\Peptide cea\linjer AEEA fevrier 2016\160314 leucocin a24 aeea 853 s1p1r2.raw

 Date : 3/21/2016 2:59:05 PM

 Method : cchromolith 5-95 en 10 min.mth

 Start Time : 0.00 min End Time : 13.00 min

 Plot Offset: -162.95 mAU

 Plot Scale: 3259.0 mAU



☎ +33 (0) 456 520 869 **∃** +33 (0) 456 520 868

38400 St Martin d'Hères France

contact@smartox-biotech.com

Peak #	Time [min]	Area [µV·s]	Height [µV]	Area [%]	Norm. Area [%]	BL	Area/Height [s]
-	0.001	0.00	0.00	0.00	0.00		
1	0.002	13.20	202.92	0.00	0.00	BB	0.0650
2	0.004	24.09	271.87	0.00	0.00	BV	0.0886
3	0.007	26.34	302.68	0.00	0.00	VB	0.0870
4	0.010	17.32	234.24	0.00	0.00	*BB	0.0739
5	6.270	170379.05	81098.26	1.60	1.60	*BB	2.1009
6	6.426	195125.07	117045.40	1.84	1.84	*BB	1.6671
7	6.498	304319.96	145871.10	2.87	2.87	*BB	2.0862
8	6.594	355984.87	202441.13	3.35	3.35	*BB	1.7585
9	6.708	9591283.16	2.79e+06	90.34	90.34	*BB	3.4412
		10617173.06	3.33e+06	100.00	100.00		

